CAC2 Childhood Cancer Community News Digest (October 28-November 3)
Assorted News from the Last Week:
The NCI Fiscal Year 2026 Professional Judgment Budget Proposal highlights promising research areas and the optimal funding needed to achieve the most rapid progress against cancer, based on the professional judgment of NCI’s leadership.
NCI’s Division of Cancer Epidemiology and Genetics has created inventories of the research conducted by its investigators on pediatric malignancies and its childhood leukemia research studies.
FDA expands approval of methotrexate to include pediatric acute lymphoblastic leukemia.
This updated NCI page provides statistics about cancer in children and teens in the United States. It also describes the common types and causes of these cancers and potential treatments.
Vorasidenib citrate (Voranigo) is approved to treat astrocytoma or oligodendroglioma brain tumors in adults and children aged 12 years and older after surgery to partially or completely remove grade 2 tumors that have an abnormal IDH1 or IDH2 gene.
A 10-year-old program at an NCI-Designated Cancer Center has had substantial success at increasing the number of adolescents and young adults with cancer who get recommended treatment and services, including greater clinical trial participation and use of fertility services.
Upcoming Webinars, Online Opportunities, and Meetings:
FDA is holding a virtual public webinar on Friday, November 8th from 2:00 pm – 3:00 pm ET on “Informed Consent – More than Just Another Document to Sign?”
A live hour on November 14 with dual Certified Child Life Specialist, Licensed Clinical Professional Counselor, and Author of The Dot Method, Kelsey Mora, focused on parenting strategies to improve communication, connection, and coping with children and teenagers. Click here for more information and to register.
Live Demo: National Childhood Cancer Registry (NCCR) Data Platform, November 12, 2024, 2:00 p.m. – 3:00 PM. ET
Please attend the BORN GALA 2024, hosted by the Neev Kolte & Brave Ronil Foundation at the Blackhawk Museum in Danville, California on November 17th, 2024. Click here for more information and to register.
Take Action:
If you or someone you know resides in Kentucky, please contact Senator Rand Paul’s office to support H.R. 3391/S. 1624 – The Gabriella Miller Kids First Research Act 2.0 a crucial program that supports research into childhood cancer and structural birth defects. Please email Ellyn Miller directly at , and request a template letter to send to his office.
CAC2 Innovation Council Recommendation: Research Opportunity for Caregivers of Children or AYA Patients with Cancer Diagnoses
Overview of the Opportunity: This is a request from the NIH Intramural Research Program for us to share information about and invite participation in a study that seeks to identify caregiver-reported and AYA-reported barriers to and facilitators of clinical trial/research study enrollment and participation.
Supporting Documentation: Studies show that child and adolescent participation in clinical trials is associated with improved cancer survival outcomes. However, there are significant racial, ethnic, and socioeconomic disparities in pediatric clinical trial enrollment. Additionally, adolescents are the least likely age group to enroll in clinical trials.
The research team hopes that by better understanding the experiences of caregivers and AYAs specifically around decision-making in regard to clinical trial participation, they can identify facilitators and modifiable barriers and implement initiatives to reduce those barriers and make clinical trials and lifesaving care more accessible to all youth with cancer.
Participation in this study involves responding to a composite survey online that takes 20 minutes to complete. The composite survey is anonymous, does not collect any personal identifiable information, and is available in English and Spanish. All participants are provided with Findhelp and Crisis Text Line as resources to help address any identified unmet needs; participants are also encouraged to communicate with their medical team about any unmet needs. This study has been approved by the NIH IRB as IRB exempt given it is an anonymous, low-risk survey that is not collecting protected health information or sensitive personally identifiable information).
The direct link to the survey is included here (https://www.surveymonkey.com/r/RKB953R).
SUBSCRIBE
Sign up to receive a copy of CAC2's free childhood cancer news digest in your inbox each week.
Categories
- Blog Posts (95)
- Explainer Post (12)
- Guest Blogs (16)
- Member Blogs (39)
- Survivorship Matters Blog (9)
- CAC2 News (25)
- Collaborative Achievements (14)
- Community News (253)
- In Memoriam (2)
- News Digest (204)
- Webinars (64)
Tags
Recent Posts
- CAC2 Childhood Cancer Community News Digest (November 26-December 1)
- CAC2 Childhood Cancer Community News Digest (November 18-25)
- Guest Blog–Conversations on Cancer – Pediatric Cancers: Navigating the Challenges Together
- Reflections from International Cancer Week 2024: A Renewed Commitment to the Fight Against Cancer
- CAC2 Childhood Cancer Community News Digest (November 11-17)